Use and Abuse of Anti-Ulcerants: A Perspective from Bangladesh

S.M. Yasir Arafat; Md. Jahid Hasan; Russell Kabir

Commentary Report


1. Wermeling M, Himmel W, Behrens G, Ahrens D. Why do GPs continue inappropriate hospital prescriptions of proton pump inhibitors? A qualitative study. Eur J Gen Pract. 2014;20(3):174–80.

2. Robinson M, Shaw K. Proton Pump Inhibitor Attitudes and Usage : A Patient Survey. 2002;27(4):202–6.

3. Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(7):CD005415

4. Moayyedi P, Talley NJ. Gastro-oesophageal refl ux disease. Lancet. 2006;367(June):2086–100

5. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane database Syst Rev. 2006;(1):CD002094.

6. Leontiadis GI , Sreedharan A , Dorward S , Barton P , Delaney B ,Howden CW , et al . Systematic reviews of the clinical eff ectiveness and cost-eff ectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding . Health Technol Assess. 2007 ; 11 : iii – iv , 1 – 164 .

7. Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: A clinical overview. Dig Liver Dis. 2008;40(8):619–26.

8. Sostres C , Gargallo CJ , Arroyo MT , Lanas A . Adverse effects of non-steroidal anti-infl ammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract . Best Pract Res Clin Gastroenterol. 2010 ; 24 : 121 – 32 .

9. Metz DC. Long-term use of proton-pump inhibitor therapy. Gastroenterol Hepatol. 2008;4(5):322–5.

10. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. Bmj. 2008;336(7634):2–3.

11. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. Bmj. 1998;317(7156):452–6.

12. Walker NM , McDonald J . An evaluation of the use of proton pump inhibitors . Pharm World Sci. 2001 ; 23 : 116 – 7 .

13. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25:333-40.

14. Mat Saad AZ, Collins N, Lobo MM, O’Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 2005;59:31-4.

15. Pham CQD, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006;40(7–8):1261–6.

16. Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of Proton Pump Inhibitors from Hospital to Community. Pharm World & Sci. 2006;28(4):189–93.

17. Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: A double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945–54.

18. Batuwitage B, Kingham JCG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-8.

19. Yang Y, Lewis J, Epstein S, Metz D. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53

20. Moayyedi P . Hip fracture and proton pump inhibitor therapy : Position statement the clinical significance of this is uncertain given that calcium. Can J Gastroenterol 2008;22(10):855–6.

21. Dial S, Delaney J, Barkun A, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficileassociated disease. JAMA 2005;294:2989-95.

22. Metz DC. G ERD.  Long-term Use of Proton-Pump Inhibitor Therapy 2008;4(5):322–5.

23. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: A retrospective cohort study. Dig Dis Sci. 2011;56(8):2349–53

24. Hungin APS, Rubin GP, O’Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract. 1999;49(443):451–3

25. National Health Service. PACT centre pages. Drugs for dyspepsia. 2006.

26. IMS Health Report. Leading therapy classes by global pharmaceutical sales.2006.

27. Arafat SMY, Hussain F, Rahman MI,  Asad SMH. Job Satisfaction Among the Medical Representative in Bangladesh: A Cross-Sectional Observation. Aust J Bus Manag Res. 2015;05(01):22–8.

28. Arafat SMY, Asad SMH Al, Hasan MJ, Ahmed Z, Halder K, Rahman MI. Prescription Modifying Marketing Factors: A Survey among the Clinicians in Bangladesh. Int J Bus Manag Invent . 2016;5(1):46–8.

29. Arafat SMY, Ahmed Z, Hasan MJ, Asad SMH. Medicine promoting marketing factors: Survey among medical representatives in Bangladesh. Int J Inf Res Rev. 2016;3(5):2315–8.

30. Arafat SMY. Doctor Patient Relationship: an Untouched Issue in Bangladesh. Int J Psychiatry. 2016;1(1):2.